5-Amino-1MQ: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 8 sources cited
Overview
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme strongly linked to obesity and metabolic dysfunction. By selectively blocking NNMT, it raises intracellular NAD+ levels and, in obese mice, shrinks fat cells without suppressing appetite or stimulating the central nervous system. It has emerged as one of the most promising anti-obesity compounds in the peptide-adjacent research space, attracting attention for its unique non-stimulant mechanism of action.
Mechanism of Action
5-Amino-1MQ selectively inhibits nicotinamide N-methyltransferase (NNMT), an enzyme highly expressed in white adipose tissue and liver that degrades NAD+ by methylating nicotinamide into 1-methylnicotinamide. When NNMT is blocked, intracellular NAD+ concentrations rise substantially, activating the sirtuin family of deacetylases — particularly SIRT1 — which serve as master regulators of cellular energy metabolism. This activation shifts adipocytes from a lipid-storage phenotype toward a metabolically active state, effectively shrinking fat cells through increased lipolysis and reduced lipogenesis. The downstream effects of NNMT inhibition are multifaceted. Elevated NAD+ promotes mitochondrial biogenesis via PGC-1α activation, increases fatty acid oxidation, and enhances the expression of uncoupling proteins (particularly UCP1) in adipose tissue, promoting non-shivering thermogenesis. NNMT inhibition also reduces the methyl donor S-adenosylmethionine (SAM) consumption in adipose tissue, potentially influencing broader epigenetic regulation of metabolic genes. How much 5-Amino-1MQ reaches the brain has not been reported; mouse work measured its distribution to fat, muscle and liver, and NNMT inhibitor treatment left food intake unchanged in those animals. Its mechanism is purely peripheral, acting directly on adipocyte metabolism. This distinguishes it fundamentally from stimulant-based weight loss compounds and even from GLP-1 agonists, which work centrally on appetite. Preclinical evidence also suggests NNMT inhibition has anti-fibrotic effects in liver tissue and may improve insulin sensitivity independent of weight loss, pointing to broader metabolic benefits beyond fat reduction.
5-Amino-1MQ Benefits: What the Research Shows
- A 2018 study published in Biochemical Pharmacology demonstrated that a potent NNMT inhibitor of this chemical class significantly reduced body weight, white adipose mass and adipocyte size in diet-induced obese mice, with no change in food intake.
- Research published in Nature showed that blocking NNMT raises NAD+ and SAM levels in adipose tissue, with activation of NAD+-dependent SIRT1 signalling.
- Preclinical data from multiple groups demonstrates that NNMT inhibition reverses diet-induced obesity and significantly improves glucose tolerance and insulin sensitivity in mouse models of metabolic syndrome.
- A 2015 study in Diabetologia showed NNMT expression is about twofold higher in omental and subcutaneous fat of patients with type 2 diabetes than in controls, with expression tracking the degree of insulin resistance, supporting the therapeutic rationale for NNMT inhibition.
- In cultured adipocytes, inhibitors of this class suppressed lipogenesis and raised intracellular NAD+ and SAM, and obese mice given a potent inhibitor had smaller adipocytes rather than reduced fat cell numbers.
- In obese mice, 5A1MQ reduced liver fat and macrophage infiltration and normalized ALT and AST, indicating possible benefit for fatty liver disease beyond weight reduction.
- Mice with NNMT knocked down gain less weight on an obesity-inducing diet and burn more energy; in full knockout mice the effect depends on sex and diet, with improved insulin sensitivity but no change in glucose tolerance.
5-Amino-1MQ Dosage
- Standard oral dose: 50 mg once daily in the morning, taken with or without food. This is the most common starting protocol for metabolic support.
- Escalated protocol: Begin at 50 mg/day for 2 weeks, then increase to 100 mg/day (50 mg twice daily — morning and early afternoon) if well tolerated and additional fat loss is desired.
- Injectable protocol: 25–50 mg subcutaneous injection daily for enhanced bioavailability, though oral formulations are more commonly used.
- Typical cycle length: 8–12 weeks on, followed by a 4-week break. Some practitioners recommend cycling 8 weeks on/4 weeks off continuously.
- Best taken in the morning to align with peak metabolic activity. Avoid evening dosing as elevated NAD+ and cellular metabolism may interfere with sleep onset in some individuals.
- Commonly stacked with AOD-9604 (250–300 mcg/day) for synergistic fat loss targeting different mechanisms — NNMT inhibition plus direct lipolysis.
- Can be combined with L-carnitine (500–1000 mg/day oral) to support the increased fatty acid oxidation driven by elevated NAD+ levels.
- No food timing restrictions, but some users report better subjective effects when taken fasted in the morning before breakfast.
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
5-Amino-1MQ Side Effects & Safety
Known Side Effects
- Mild gastrointestinal discomfort (nausea, loose stools) reported by some users, particularly at higher doses or when taken on an empty stomach.
- Occasional headaches during the first week of use, typically resolving as the body adjusts to altered NAD+ metabolism.
- Potential for mild insomnia if taken too late in the day, likely related to increased cellular metabolic activity.
- Theoretical risk of disrupting methylation pathways at very high doses, though no clinical evidence of this at standard dosing.
- Some users report mild skin flushing, potentially related to NAD+-dependent vasodilation pathways.
- Long-term safety data in humans is limited — most evidence is preclinical, and extended use beyond 12 weeks lacks robust human safety data.
Safety Profile
What is known about 5-Amino-1MQ safety comes from rodent studies, where no adverse effects were observed at the doses tested and food intake was unchanged. Heart rate, blood pressure and central nervous system effects have not been reported, and no dose margin over a human-equivalent dose has been established. However, human clinical trial data is limited, and most safety information comes from animal models and anecdotal user reports. Contraindications include caution in individuals with methylation-related conditions (e.g., MTHFR polymorphisms) due to the theoretical impact on SAM metabolism, though clinical significance is unestablished. It should not be combined with other NAD+-boosting supplements (NMN, NR) at high doses without monitoring, as excessive NAD+ elevation is theoretically possible. Individuals with liver or kidney impairment should use reduced doses or avoid use until more safety data is available. Not recommended during pregnancy or breastfeeding due to lack of reproductive toxicity data.
What to Expect
Weeks 1–2: Most users notice subtle increases in energy and body temperature as cellular metabolism ramps up. Fat loss is not yet visible but metabolic changes are beginning. Some users report mild GI adjustment during this period. Weeks 3–4: Measurable changes in body composition begin to appear. Users commonly report reduced abdominal bloating, slightly improved definition, and continued steady energy without stimulant-like effects. Clothes may begin fitting differently. Weeks 5–8: This is the primary window of visible fat loss. Users typically report 3–6 lbs of fat loss without dietary changes, with the most pronounced effects in those combining 5-Amino-1MQ with regular exercise and caloric awareness. Visceral fat reduction may be reflected in improved waist measurements. Weeks 9–12: Continued gradual fat loss with diminishing incremental returns. Some users plateau, which is the typical signal to conclude the cycle. Metabolic benefits (improved fasting glucose, better energy) tend to persist for several weeks after cessation.
Common Stacks
AOD-9604
Complementary fat loss mechanisms — 5-Amino-1MQ increases NAD+ and cellular fat metabolism while AOD-9604 directly stimulates lipolysis via the beta-3 adrenergic receptor. Together they attack fat storage from two different angles.
MOTS-c
Both compounds enhance mitochondrial function and metabolic efficiency. MOTS-c activates AMPK and improves insulin sensitivity, synergizing with 5-Amino-1MQ's NAD+-driven metabolic boost.
L-Carnitine
L-carnitine shuttles fatty acids into mitochondria for oxidation. When 5-Amino-1MQ upregulates fat oxidation pathways, L-carnitine ensures the released fatty acids are efficiently burned rather than re-esterified.
Storage & Handling
Oral capsules: Store at room temperature (59–86°F / 15–30°C) in a cool, dry place away from direct sunlight and moisture. Shelf life is typically 12–24 months from manufacture. Injectable formulations: Store lyophilized powder refrigerated (36–46°F / 2–8°C). After reconstitution with bacteriostatic water, refrigerate and use within 4 weeks. Do not freeze reconstituted solution.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018.
- Babula JJ, Bui D, Stevenson HL, et al. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab. 2024.
- Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014.
- Kannt A, Pfenninger A, Teichert L, et al. Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. Diabetologia. 2015.
- Brachs S, Polack J, Brachs M, et al. Genetic Nicotinamide N-Methyltransferase (Nnmt) Deficiency in Male Mice Improves Insulin Sensitivity in Diet-Induced Obesity but Does Not Affect Glucose Tolerance. Diabetes. 2019.
- Sampson CM, Dimet AL, Neelakantan H, et al. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Sci Rep. 2021.
- Kannt A, Rajagopal S, Kadnur SV, et al. A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders. Sci Rep. 2018.
- Sun WD, Zhu XJ, Li JJ, et al. Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome. Front Pharmacol. 2024.
Related Peptides
Track 5-Amino-1MQ in Your Protocol
Log your 5-Amino-1MQ doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free